{"success":true,"data":{"pressRelease":{"id":"133789","rtpr_id":"nGNX89Hzqv","ticker":"BIOA","exchange":"NASDAQ","all_tickers":["BIOA"],"title":"BioAge Labs to Present at Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-09-02T12:00:01.266Z","article_body":"EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(NASDAQ: BIOA) (\"BioAge\", \"the Company\"), a clinical-stage biotechnology\ncompany developing therapeutic product candidates for cardiometabolic diseases\nby targeting the biology of human aging, today announced that the Company will\nparticipate in the following upcoming investor conferences:\n* Citi Biopharma Back to School Conference (New York, September 9–10, 2026):\nKristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a\nfireside chat on Wednesday, September 9 at 11:20–11:55 AM EDT. Kristen\nFortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings.\nTo access the live webcast of the presentation, register here\n(https://kvgo.com/2026-biopharma-conference/bioage-labs-sep-2026).\n* Cantor Global Healthcare Conference (New York, September 9–11, 2026):\nKristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a\nfireside chat on Friday, September 11 at 10:20–10:50 AM EDT. Kristen Fortney\nand Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access\nthe live webcast of the presentation, register here\n(https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=67995299&checkCompany=1&checkEmail=1&checkName=1).\n* Morgan Stanley 24th Annual Global Healthcare Conference (New York, September\n14–16, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy\nOfficer, are scheduled to participate in a fireside chat on Wednesday,\nSeptember 16 at 10:00–10:35 AM EDT, and will participate in one-on-one\nmeetings. To access the live webcast of the presentation, register here\n(https://cc.webcasts.com/morg007/091426a_js/?entity=147_FQWDUJW).\nReplays of the webcasts will be available in the investor section of the\nCompany's website at https://ir.bioagelabs.com/, and will be archived for 30\ndays following the presentations.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company’s lead product candidate, BGE-102, is a potent,\norally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for diseases driven by inflammation, including retinal diseases such\nas diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial\ndemonstrating a well-tolerated profile and potential best-in-class reductions\nin hsCRP and other inflammatory biomarkers in participants with obesity and\nelevated inflammatory markers such as hsCRP. Phase 2 proof-of-concept data are\nanticipated in the second half of 2026, and Phase 1b/2a diabetic macular edema\nproof-of-concept data are anticipated in mid-2027. The Company is also\ndeveloping long-acting injectable and oral small molecule APJ agonists for\nobesity. BioAge’s additional preclinical programs, which leverage insights\nfrom the Company’s proprietary discovery platform built on human longevity\ndata, address key pathways involved in metabolic aging.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX89Hzqv","title":"BioAge Labs to Present at Upcoming Investor Conferences","author":"Globe Newswire","ticker":"BIOA","created":"2026-09-02T12:00:01.266Z","tickers":["BIOA"],"exchange":"NASDAQ","article_body":"EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(NASDAQ: BIOA) (\"BioAge\", \"the Company\"), a clinical-stage biotechnology\ncompany developing therapeutic product candidates for cardiometabolic diseases\nby targeting the biology of human aging, today announced that the Company will\nparticipate in the following upcoming investor conferences:\n* Citi Biopharma Back to School Conference (New York, September 9–10, 2026):\nKristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a\nfireside chat on Wednesday, September 9 at 11:20–11:55 AM EDT. Kristen\nFortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings.\nTo access the live webcast of the presentation, register here\n(https://kvgo.com/2026-biopharma-conference/bioage-labs-sep-2026).\n* Cantor Global Healthcare Conference (New York, September 9–11, 2026):\nKristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a\nfireside chat on Friday, September 11 at 10:20–10:50 AM EDT. Kristen Fortney\nand Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access\nthe live webcast of the presentation, register here\n(https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=67995299&checkCompany=1&checkEmail=1&checkName=1).\n* Morgan Stanley 24th Annual Global Healthcare Conference (New York, September\n14–16, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy\nOfficer, are scheduled to participate in a fireside chat on Wednesday,\nSeptember 16 at 10:00–10:35 AM EDT, and will participate in one-on-one\nmeetings. To access the live webcast of the presentation, register here\n(https://cc.webcasts.com/morg007/091426a_js/?entity=147_FQWDUJW).\nReplays of the webcasts will be available in the investor section of the\nCompany's website at https://ir.bioagelabs.com/, and will be archived for 30\ndays following the presentations.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company’s lead product candidate, BGE-102, is a potent,\norally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for diseases driven by inflammation, including retinal diseases such\nas diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial\ndemonstrating a well-tolerated profile and potential best-in-class reductions\nin hsCRP and other inflammatory biomarkers in participants with obesity and\nelevated inflammatory markers such as hsCRP. Phase 2 proof-of-concept data are\nanticipated in the second half of 2026, and Phase 1b/2a diabetic macular edema\nproof-of-concept data are anticipated in mid-2027. The Company is also\ndeveloping long-acting injectable and oral small molecule APJ agonists for\nobesity. BioAge’s additional preclinical programs, which leverage insights\nfrom the Company’s proprietary discovery platform built on human longevity\ndata, address key pathways involved in metabolic aging.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T12:00:01.307555855Z","server_sent_at_ms":1788350401307},"received_at":"2026-09-02T12:00:01.392Z","source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355053/0/en/bioage-labs-to-present-at-upcoming-investor-conferences.html"},"analysis":{"id":"122687","press_release_id":"133789","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"BioAge Labs will present at three September investor conferences: the Citi Biopharma Back to School Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference, all in New York.\n\nCEO and co-founder Kristen Fortney and CFO Dov Goldstein will headline fireside chats and one-on-one meetings at Citi and Cantor, with Chief Strategy Officer BJ Sullivan joining the Morgan Stanley fireside chat; webcast replays will be archived for 30 days.\n\nThe appearances come ahead of a catalyst-heavy stretch: Phase 2 proof-of-concept data for lead candidate BGE-102, an oral NLRP3 inhibitor targeting cardiometabolic and retinal inflammation, are expected in the second half of 2026, with Phase 1b/2a diabetic macular edema data anticipated in mid-2027.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference calendar; watch the September fireside chats for color ahead of the BGE-102 Phase 2 proof-of-concept readout in 2H 2026."},"keyFigures":{"customDimensions":{"phase2_poc_data_expected":"second half of 2026","phase1b2a_dme_poc_data_expected":"mid-2027"}},"namedEntities":{"people":[{"name":"Kristen Fortney, PhD","role":"CEO and co-founder"},{"name":"Dov Goldstein, MD","role":"CFO"},{"name":"BJ Sullivan, PhD","role":"Chief Strategy Officer"}],"products":["BGE-102","APJ agonists (long-acting injectable and oral small molecule)"],"companies":[{"name":"BioAge Labs, Inc.","ticker":"BIOA","relationship":"filer"},{"name":"Citi","relationship":"conference host (Citi Biopharma Back to School Conference)"},{"name":"Cantor","relationship":"conference host (Cantor Global Healthcare Conference)"},{"name":"Morgan Stanley","relationship":"conference host (24th Annual Global Healthcare Conference)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations scheduling announcement for conference participation; no new clinical, financial, or strategic information disclosed. The trial data timelines cited are boilerplate from the company description, not new guidance."},"tickerRelevance":{"others":[],"primary":"BIOA"},"globalImportance":8,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-ir-conference-schedule","issuerAuthored":true,"newInformation":"none","catalystContext":"BGE-102 Phase 2 PoC data expected 2H 2026"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"BioAge Labs will present at three September investor conferences: the Citi Biopharma Back to School Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference, all in New York.\n\nCEO and co-founder Kristen Fortney and CFO Dov Goldstein will headline fireside chats and one-on-one meetings at Citi and Cantor, with Chief Strategy Officer BJ Sullivan joining the Morgan Stanley fireside chat; webcast replays will be archived for 30 days.\n\nThe appearances come ahead of a catalyst-heavy stretch: Phase 2 proof-of-concept data for lead candidate BGE-102, an oral NLRP3 inhibitor targeting cardiometabolic and retinal inflammation, are expected in the second half of 2026, with Phase 1b/2a diabetic macular edema data anticipated in mid-2027.","key_figures":{"customDimensions":{"phase2_poc_data_expected":"second half of 2026","phase1b2a_dme_poc_data_expected":"mid-2027"}},"named_entities":{"people":[{"name":"Kristen Fortney, PhD","role":"CEO and co-founder"},{"name":"Dov Goldstein, MD","role":"CFO"},{"name":"BJ Sullivan, PhD","role":"Chief Strategy Officer"}],"products":["BGE-102","APJ agonists (long-acting injectable and oral small molecule)"],"companies":[{"name":"BioAge Labs, Inc.","ticker":"BIOA","relationship":"filer"},{"name":"Citi","relationship":"conference host (Citi Biopharma Back to School Conference)"},{"name":"Cantor","relationship":"conference host (Cantor Global Healthcare Conference)"},{"name":"Morgan Stanley","relationship":"conference host (24th Annual Global Healthcare Conference)"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T13:20:52.132Z","global_importance":8,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-ir-conference-schedule","issuerAuthored":true,"newInformation":"none","catalystContext":"BGE-102 Phase 2 PoC data expected 2H 2026"}},"durationMs":101825,"modelName":"glm-4.7"}}